All In Biotech

Drug Trial Radar · NCT04649385

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

157

Actual

Start

Mar 4, 2021

Primary completion

Oct 17, 2025

Study completion May 15, 2026

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Dec 2, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • BGB-15025Drug

    Administered orally once or twice daily (QD or BID)

  • TislelizumabDrug

    Administered 200 mg intravenous (IV) infusion

  • CarboplatinDrug

    Administered intravenously

  • CisplatinDrug

    Administered intravenously

  • PemetrexedDrug

    Administered intravenously

  • OxaliplatinDrug

    Administered intravenously

  • CapecitabineDrug

    Administered intravenously

  • PaclitaxelDrug

    Administered intravenously

  • nab-paclitaxelDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: Number of participants with dose limiting toxicities (DLTs)Time frame: Up to 3 Years
  2. Phase 1a: Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to 4 Years
  3. Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)Time frame: Up to 4 years
  4. The maximum tolerated dose (MTD) of BGB-15025Time frame: Up to 3 Years
  5. Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapyTime frame: Up to 3 years
  6. RDFE of BGB-15025 in combination with tislelizumabTime frame: Up to 3 years
  7. Phase 1b: Overall Response Rate (ORR) as assessed by the investigatorTime frame: Up to 2 years

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Icahn School of Medicine At Mount Sinai

    New York, New York

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas

  • Ut Health San Antonio Mays Cancer Center

    San Antonio, Texas

  • Prince of Wales Hospital

    Randwick, New South Wales, Australia

  • Ashford Cancer Centre Research Northeast

    Windsor Gardens, South Australia, Australia

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Auckland City Hospital

    Auckland, New Zealand

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Samsung Medical Center

    GangnamGu, Seoul Teugbyeolsi, South Korea

  • The Catholic University of Korea, Seoul St Marys Hospital

    SeochoGu, Seoul Teugbyeolsi, South Korea

  • Severance Hospital Yonsei University Health System

    SeodaemunGu, Seoul Teugbyeolsi, South Korea

  • Asan Medical Center

    SongpaGu, Seoul Teugbyeolsi, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.